Shares of other companies:
Wall Street Brunch: Here Comes Nvidia
May 19, 2024
A.O. Smith: Great Company, Inferior Investment
May 18, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
ACAD Stock News and Mentions of ACADIA Pharmaceuticals Inc. Stocktwits
Updated: May 20, 2024 (09:13)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where ACADIA Pharmaceuticals Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of ACADIA Pharmaceuticals Inc. (ACAD).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the ACADIA Pharmaceuticals stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of ACADIA Pharmaceuticals Inc. (ACAD)
May 9, 2024 (09:59) / "Zacks Commentary" (by Zacks Equity Research)
Acadia ( ACAD ) Q1 Earnings Surpass Estimates, Revenues Miss
Acadia's (ACAD) earnings in the first quarter of 2024 beat the Zacks Consensus Estimate, while revenues miss the same.
In Article Trend: Neutral
May 8, 2024 (21:15) / "Zacks Commentary" (by Zacks Equity Research)
Acadia Pharmaceuticals ( ACAD ) Tops Q1 Earnings Estimates
Acadia (ACAD) delivered earnings and revenue surprises of 150% and 0.52%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend: Neutral
May 7, 2024 (21:40) / "Zacks Commentary" (by Zacks Equity Research)
Ligand Pharmaceuticals ( LGND ) Tops Q1 Earnings Estimates
Ligand (LGND) delivered earnings and revenue surprises of 6.19% and 4.68%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend: Somewhat-Bullish
May 6, 2024 (14:40) / "Zacks Commentary" (by Kinjel Shah)
Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?
Let us look at five drug, generic companies, PRGO, IOVA, VTRS, TEVA and ACAD, which are gearing up for their earnings release this week.
In Article Trend: Neutral
May 2, 2024 (14:01) / "Zacks Commentary" (by Zacks Equity Research)
Insmed ( INSM ) Expected to Beat Earnings Estimates: Should You Buy?
Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In Article Trend: Neutral
May 2, 2024 (13:28) / "Stocknews.com" (by StockNews.com Staff)
ACAD: Buy Alert: 3 Pharma Stocks Under $20 to Invest in Now
In the ever-evolving landscape of pharmaceutical sector, the ascent of Pharma 4.0 heralds a transformative era. Besides, the growing interest among investors in pharmaceutical stocks is highlighted by the impressive performance of the Invesco Dynamic Pharmaceuticals ETF ( PJP ) , which has seen a ...
In Article Trend: Neutral
May 1, 2024 (14:01) / "Zacks Commentary" (by Zacks Equity Research)
Acadia Pharmaceuticals ( ACAD ) Earnings Expected to Grow: Should You Buy?
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In Article Trend: Neutral
April 12, 2024 (10:12) / "Stocknews.com" (by StockNews.com Staff)
ALPMY: 3 Affordable Pharma Stocks to Buy for Portfolio Gains
The pharmaceutical industry is undergoing a transformative boom, leveraging digital platforms, big data analytics, cloud computing, and AI to drive innovation. Moreover, the growing demand for personalized drugs and increased R&D activities should give an additional boost to the already ...
In Article Trend: Somewhat-Bullish
April 1, 2024 (11:54) / "Business Insider" (by PRESS RELEASE ACCESSWIRE)
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA ... - Markets Insider ...
In Article Trend: Neutral
March 28, 2024 (15:30) / "Zacks Commentary" (by Zacks Equity Research)
Why Is Acadia ( ACAD ) Down 23.4% Since Last Earnings Report?
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In Article Trend: Neutral
March 27, 2024 (12:50) / "Zacks Commentary" (by Zacks Equity Research)
Stoke Therapeutics ( STOK ) Up on Upbeat Dravet Syndrome Study Data
Stoke Therapeutics (STOK) gains on meaningful clinical data from STK-001 studies for the treatment of Dravet syndrome.
In Article Trend: Neutral
Related stocks from Healthcare sector
This website uses cookies to ensure you get the best experience on our website